EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?

Konstantinos Drougkas, Konstantinos Karampinos, Ioannis Karavolias, Ioannis-Alexios Koumprentziotis, Ioanna Ploumaki, Efthymios Triantafyllou, Ioannis Trontzas, Elias Kotteas

Journal of Cancer Research and Clinical Oncology · 2023-06 · 149 (6) · 2709-2734

DOI: 10.1007/s00432-022-04547-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cancer Research and Clinical Oncology, online erschienen am 24.12.2022. Verfasst von Konstantinos Drougkas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, Sotiria General Hospital, National and Kapodistrian University of Athens, 152 Mesogeion Avenue, 11527, Athens, Greece. kostasdrougas7@…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms, Hematologic Neoplasms. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Athens.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Chimeric Antigen Receptor (CAR)-T cell therapy is a form of adoptive cell therapy that has demonstrated tremendous results in the treatment of hematopoietic malignancies, leading to the US Food and Drug Administration (FDA) approval of four CD19-targeted CAR-T cell products. With the unprecedented success of CAR-T cell therapy in hematological malignancies, hundreds of preclinical studies and clinical trials are currently undergoing to explore the translation of this treatment to solid tumors. However, the clinical experience in non-hematologic malignancies has been less encouraging, with only a few patients achieving complete responses. Tumor-associated antigen heterogeneity, inefficient CAR-T cell trafficking and the immunosuppressive tumor microenvironment are considered as the most pivotal roadblocks in solid tumor CAR-T cell therapy. Materials and methods We reviewed the relevant literature/clinical trials for CAR-T cell immunotherapy for solid tumors from Pubmed and ClinicalTrials.gov.

Conclusion

Herein, we provide an update on solid tumor CAR-T cell clinical trials, focusing on the studies with published results. We further discuss some of the key hurdles that CAR-T cell therapy is encountering for solid tumor treatment as well as the strategies that are exploited to overcome these obstacles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenNeoplasmsHematologic NeoplasmsHumansReceptors, Antigen, T-CellImmunotherapyImmunotherapy, AdoptiveT-LymphocytesTumor Microenvironment

Stichwörter der Autor:innen

CAR T cellsChimeric antigen receptorImmunotherapySolid tumorsTumor microenvironment

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Oncology Unit, Sotiria General Hospital, National and Kapodistrian University of Athens, 152 Mesogeion Avenue, 11527, Athens, Greece. kostasdrougas7@gmail.com.
  • Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Attica, Greece. kostasdrougas7@gmail.com.
  • Oncology Unit, Sotiria General Hospital, National and Kapodistrian University of Athens, 152 Mesogeion Avenue, 11527, Athens, Greece.
  • Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Attica, Greece.
  • Department of Pathology, Yale University School of Medicine, New Haven, USA, CT.

Förderung

  • University of Athens

Zitieren

APA

Drougkas, K., Karampinos, K., Karavolias, I., Koumprentziotis, I. A., Ploumaki, I., Triantafyllou, E., Trontzas, I., & Kotteas, E. (2023). Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?. Journal of Cancer Research and Clinical Oncology, 149(6), 2709-2734. https://doi.org/10.1007/s00432-022-04547-4

Vancouver

Drougkas K, Karampinos K, Karavolias I, Koumprentziotis IA, Ploumaki I, Triantafyllou E, et al. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?. Journal of Cancer Research and Clinical Oncology. 2023;149(6):2709-2734. doi:10.1007/s00432-022-04547-4

BibTeX
@article{Drougkas2023,
  author = {Drougkas, Konstantinos and Karampinos, Konstantinos and Karavolias, Ioannis and Koumprentziotis, Ioannis-Alexios and Ploumaki, Ioanna and Triantafyllou, Efthymios and Trontzas, Ioannis and Kotteas, Elias},
  title = {Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2023},
  volume = {149},
  number = {6},
  pages = {2709--2734},
  doi = {10.1007/s00432-022-04547-4}
}
Kostenlos starten →